Drug Delivery
Nanoparticle-based drug delivery systems for targeted therapeutics
Nanobiotix
Paris, France
Clinical-stage biotechnology company pioneering nanomedicine with first-in-class radioenhancers for cancer treatment
Arrowhead Research
Pasadena, United States
Biopharmaceutical company developing targeted RNAi therapeutics using proprietary TRiM platform
BIND Therapeutics
Cambridge, United States
BIND Therapeutics, founded in 2007 and based in Cambridge, Massachusetts, pioneered the Accurin platform of polymeric nanoparticles for targeted cancer drug delivery, representing one of the most advanced clinical applications of nanomedicine. With over $150 million in funding and 100-200 employees, BIND developed sophisticated nanotechnology designed to precisely deliver chemotherapy agents to tumor cells while minimizing systemic toxicity. The company emerged from groundbreaking research at MIT and Harvard on controlled drug delivery using biodegradable polymer nanoparticles. BIND's Accurin nanoparticles were engineered with extraordinary precision, incorporating multiple functional components: a biodegradable polymer core loaded with chemotherapy drugs, a protective hydrophilic polymer shell to evade immune system clearance, and targeting ligands that bind to specific molecules overexpressed on cancer cells. This multicomponent design addressed fundamental challenges in cancer treatment—delivering sufficient drug to tumors while avoiding damage to healthy tissues. The company's lead candidate, BIND-014, consisted of docetaxel chemotherapy encapsulated in nanoparticles displaying PSMA-targeting ligands, designed for prostate cancer treatment. BIND advanced multiple nanoparticle candidates through clinical trials, generating valuable data on nanomedicine performance in humans. The company's clinical programs demonstrated that carefully designed nanoparticles could alter drug biodistribution, enhance tumor accumulation, and potentially improve therapeutic indices. BIND employed sophisticated polymer chemistry and formulation sciences to create nanoparticles with controlled sizes (typically 50-100 nanometers), precise drug loading, and sustained release profiles. The company developed scalable manufacturing processes meeting pharmaceutical GMP standards—a significant achievement given the complexity of multi-functional nanoparticles. Throughout its existence, BIND contributed substantially to understanding how nanoparticle properties including size, surface chemistry, and targeting ligands influence biological fate and therapeutic efficacy. Despite promising preclinical data and successful clinical trial execution, BIND faced challenges common to nanomedicine development including complex regulatory pathways, high development costs, and difficulty demonstrating sufficient therapeutic advantages over existing treatments. In 2016, facing financial pressures, BIND was acquired by Pfizer, which subsequently discontinued the programs, highlighting the challenging economics of nanomedicine development. Nevertheless, BIND's legacy includes important contributions to nanomedicine science, demonstration that sophisticated nanoparticles can be manufactured at pharmaceutical scales, and clinical data advancing understanding of nanoparticle behavior in humans. The company's experience provides valuable lessons for the nanomedicine field regarding the gap between preclinical promise and clinical reality, the importance of selecting appropriate patient populations, and the need for compelling therapeutic differentiation to justify nanomedicine's inherent complexity.
Selecta Biosciences
Watertown, United States
Selecta Biosciences, Inc., founded in 2007 and based in Watertown, Massachusetts, is a clinical-stage biopharmaceutical company developing its proprietary ImmTOR nanoparticle platform to address a critical challenge in biologics therapy—unwanted immune responses that reduce treatment efficacy. Publicly traded on NASDAQ (SELB) with over $300 million in funding and 100-200 employees, Selecta has pioneered synthetic vaccine particles (SVP) that can selectively modulate immune responses, potentially enabling repeat administration of therapeutic proteins and gene therapies. The company emerged from research on how nanoparticle properties influence immune system activation, discovering that specific nanoparticle designs could induce immune tolerance rather than immunogenicity. Selecta's ImmTOR platform consists of biodegradable polymer nanoparticles incorporating immunomodulatory small molecules (typically rapamycin analogs) that are taken up by immune cells, inducing tolerance to co-administered therapeutic agents. This approach addresses a major limitation of protein therapeutics and gene therapies—the development of neutralizing antibodies that reduce or eliminate treatment efficacy with repeated dosing. For example, many patients with gout receiving enzyme replacement therapy develop anti-drug antibodies that neutralize the therapeutic enzyme, requiring treatment discontinuation. Selecta's lead program, SEL-212, combines ImmTOR nanoparticles with pegsiticase enzyme therapy for severe gout, with clinical trials demonstrating reduced immunogenicity and improved sustained therapeutic response. The company has expanded its platform to address immunogenicity challenges in gene therapy, where immune responses against viral vectors or therapeutic proteins can limit treatment durability. Selecta has established partnerships with major pharmaceutical companies including Sarepta Therapeutics and Asklepios BioPharmaceutical to apply ImmTOR technology to gene therapy programs for muscular dystrophies and other genetic diseases. The company's nanoparticles are engineered with precise sizes (typically 200-500 nanometers), controlled drug loading, and surface properties optimized for uptake by specific immune cell populations. Selecta has developed manufacturing processes producing clinical-grade ImmTOR nanoparticles at scales required for therapeutic applications, addressing a key challenge in nanomedicine translation. The company's approach represents sophisticated application of nanotechnology principles—using nanoparticle properties to program specific biological responses rather than simply delivering drugs. Selecta's clinical programs have generated important data on how synthetic nanoparticles can modulate human immune systems, contributing to fundamental understanding of nanoparticle immunology. As gene therapies and protein biologics become increasingly important in medicine, addressing immunogenicity challenges will be crucial for enabling repeat dosing and expanding patient populations. Selecta's ImmTOR platform offers a potentially broadly applicable solution to this critical problem, positioning the company at the intersection of nanomedicine and immunotherapy, two of the most promising areas in biopharmaceutical development.
NanoViricides
Shelton, United States
Developer of nanoviricide drugs designed to attack and destroy viruses
CytImmune Sciences
Rockville, United States
Developer of gold nanoparticle-based cancer therapeutics
Nanobio Corporation
Ann Arbor, United States
Developer of nanoemulsion-based products for infection and vaccine delivery
Liquidia Technologies
Morrisville, United States
Developer of PRINT technology for precisely engineered drug particles
NanoMedical Systems
Austin, United States
Developer of nanochannel drug delivery implants for sustained therapeutic release
Nanosphere Health Sciences
Vancouver, Canada
Developer of NanoSphere Delivery System for enhanced bioavailability of cannabinoids
Tarveda Therapeutics
Watertown, United States
Developer of miniature drug conjugates for targeted cancer therapy
National Nanotechnology Initiative
Washington, United States
US government R&D initiative coordinating nanotechnology research across federal agencies
Arch Venture Partners
Chicago, United States
Venture capital firm focusing on early-stage technology companies including nanotech
Acuitas Therapeutics
Vancouver, Canada
Leading developer of lipid nanoparticle (LNP) delivery systems for nucleic acid therapeutics, partner for COVID-19 vaccines
Alnylam Pharmaceuticals
Cambridge, United States
Pioneer in RNAi therapeutics using lipid nanoparticle delivery for treatment of genetic diseases
Nanocure
Tel Aviv, Israel
Nanocure, established in 2015 in Tel Aviv, Israel, is an innovative nanomedicine company focused on developing next-generation cancer therapies through advanced nanoparticle-based drug delivery systems. The company's proprietary platform leverages the unique properties of engineered nanoparticles to achieve precise targeting of cancer cells while minimizing damage to healthy tissue, addressing one of the most significant challenges in oncology treatment. Nanocure's targeted nanoparticle therapeutics are designed to overcome the limitations of conventional chemotherapy, which often causes severe side effects due to non-selective distribution throughout the body. The company's nanoparticle formulations utilize sophisticated surface modifications, including targeting ligands and stealth coatings, to enhance circulation time, improve tumor accumulation through the enhanced permeability and retention effect, and facilitate active targeting to specific cancer cell markers. This multifaceted approach enables higher drug concentrations at tumor sites while reducing systemic exposure and associated toxicities. The technology platform is versatile, capable of encapsulating various therapeutic agents including small molecule drugs, peptides, and nucleic acids, making it applicable to multiple cancer types and treatment modalities. Nanocure's nanoparticles are engineered at the nanoscale (typically 10-200 nanometers) to optimize biological interactions, cellular uptake, and intracellular drug release. The company has secured over $15 million in funding to advance its pipeline through preclinical and clinical development stages. Israel's strong biotechnology ecosystem and expertise in nanomedicine provide Nanocure with access to world-class research facilities, clinical networks, and regulatory support. As cancer treatment increasingly moves toward personalized medicine and targeted therapies, Nanocure's nanoparticle platform represents a significant advancement in delivering more effective and safer cancer treatments, positioning the company as an important player in the rapidly evolving field of cancer nanotherapy.
Codiak BioSciences
Cambridge, United States
Codiak BioSciences, founded in 2015 in Cambridge, Massachusetts, is a pioneering biotechnology company at the forefront of exosome-based therapeutics. The company has developed the proprietary engEx platform, which engineers exosomes—naturally occurring nanovesicles (30-150 nanometers) secreted by cells—as sophisticated drug delivery vehicles. Unlike synthetic nanoparticles, exosomes offer inherent biocompatibility, low immunogenicity, and natural ability to cross biological barriers, making them ideal carriers for therapeutic payloads. Codiak's engEx technology precisely modifies exosomes to display specific targeting molecules on their surface while loading therapeutic cargo inside, creating programmable nanomedicines with enhanced tissue specificity and therapeutic efficacy. The company's lead programs include exoSTING, an exosome-delivered STING agonist for cancer immunotherapy, and exoIL-12, which delivers interleukin-12 for tumor treatment. These engineered exosomes leverage the body's natural intercellular communication system to deliver potent immunomodulatory agents directly to target cells, potentially revolutionizing cancer treatment with improved safety profiles compared to conventional delivery methods. Codiak has raised over $300 million in funding, reflecting significant investor confidence in exosome therapeutics. The Cambridge location places Codiak at the heart of the biotech innovation ecosystem, with access to world-renowned research institutions and clinical infrastructure. The company employs between 100-200 specialists in molecular biology, nanotechnology, and clinical development. Exosomes represent a convergence of cell biology and nanotechnology, and Codiak's platform addresses critical challenges in drug delivery including tumor penetration, immune evasion, and payload stability. As the field of nanomedicine evolves beyond synthetic nanoparticles, Codiak's focus on biological nanovesicles positions it as a leader in next-generation therapeutic delivery, with potential applications extending beyond oncology to neurodegenerative diseases, rare disorders, and vaccines.
Nanexa
Uppsala, Sweden
Developer of PharmaShell nanocoating technology for controlled drug release
NanoVation Therapeutics
Vancouver, Canada
Developer of next-generation lipid nanoparticle delivery systems for RNA therapeutics
Verve Therapeutics
Boston, United States
Gene editing company using lipid nanoparticle delivery for cardiovascular disease treatment
Sirnaomics
Gaithersburg, United States
Clinical-stage biopharmaceutical company developing RNAi therapeutics using polypeptide nanoparticle delivery
CureVac
Tubingen, Germany
Pioneer in mRNA technology using lipid nanoparticle delivery for vaccines and therapeutics
Genevant Sciences
Cambridge, United States
Developer of lipid nanoparticle and ligand conjugate delivery systems for genetic medicines
Arcturus Therapeutics
San Diego, United States
Developer of LUNAR lipid nanoparticle delivery platform for mRNA medicines
Silence Therapeutics
London, United Kingdom
Pioneer in precision RNAi medicines using mRNAi GOLD platform with GalNAc delivery
Dicerna Pharmaceuticals
Lexington, United States
Developer of GalXC RNAi platform for targeted gene silencing therapeutics
Nanobiotix SA
Cambridge, United States
Clinical-stage nanomedicine company developing first-in-class radioenhancers using hafnium oxide nanoparticles
NanoCarrier
Kashiwa, Japan
Developer of micellar nanoparticle drug delivery systems for cancer treatment
Nippon Kayaku
Tokyo, Japan
Pharmaceutical and chemical company with nanomedicine portfolio including micellar formulations
Starpharma Holdings
Melbourne, Australia
World leader in dendrimer nanotechnology for drug delivery and pharmaceutical applications
NanoMedSyn
Montpellier, France
Developer of MUSIC nanoparticle platform for targeted drug delivery
Arrowhead Pharmaceuticals
Pasadena, United States
Leader in RNAi therapeutics using targeted delivery
Nanosphere Biosciences
Boulder, United States
Developer of nanobubble-based therapeutic delivery systems
NanoMedica
San Diego, United States
Developer of nanoparticle-based cancer therapeutics
NanoPass Technologies
Ness Ziona, Israel
Developer of microneedle drug delivery systems
Nanoform Finland
Helsinki, Finland
Developer of controlled expansion of supercritical solutions for drug nanoforming
Translate Bio
Lexington, United States
mRNA therapeutics company with proprietary LNP technology, acquired by Sanofi
Mina Therapeutics
London, United Kingdom
Small activating RNA therapeutics with LNP delivery
Tidal Therapeutics
Cambridge, United States
LNP-based in vivo gene therapy for immune cells, acquired by Sanofi
ReNAgade Therapeutics
Cambridge, United States
RNA delivery technology for extrahepatic targets
NanoMedTrix
Berlin, Germany
Nanoparticle-based immunotherapy platform
SciSparc
Tel Aviv, Israel
Nano-drug delivery for CNS disorders
Nano Therapeutics
Mumbai, India
Nano-based drug delivery systems for cancer therapy
NanoBio (BlueWillow Biologics)
Ann Arbor, United States
Nanoemulsion-based vaccines and therapeutics
NanoTherapeutics
Alachua, United States
Biopharmaceutical nanotechnology development
Nanoform
Helsinki, Finland
Controlled expansion of supercritical solutions for drug nanoparticle engineering
Celgene (Bristol-Myers Squibb)
Summit, United States
Oncology and immunology therapeutics using nanoparticle formulations
Abraxis BioScience
Los Angeles, United States
Pioneer of nanoparticle albumin-bound (nab) technology for cancer drugs
NanoCarrier Co., Ltd.
Chiba, Japan
Polymeric micellar nanoparticle drug delivery for cancer therapeutics
LNP Japan
Tokyo, Japan
Lipid nanoparticle manufacturing services for RNA therapeutics
BioDynamics Laboratory
Tokyo, Japan
Nanogel and polymer technology for drug delivery applications
Starpharma
Melbourne, Australia
Dendrimer nanotechnology for antiviral and oncology therapeutics
NanoBio Corporation
Ann Arbor, United States
Nanoemulsion technology for intranasal vaccines and skin treatments
Nanobio2Pharma
Bordeaux, France
Nanoparticle drug formulation and CDMO services
Nanomerics
London, United Kingdom
Molecular envelope technology for enhanced drug delivery
Midatech Pharma
Abingdon, United Kingdom
Gold nanoparticle drug conjugates for oncology therapeutics
Ceramisphere
Sydney, Australia
Ceramic nanoparticle drug delivery systems
Camurus
Lund, Sweden
FluidCrystal lipid-based drug delivery systems
Ethris GmbH
Planegg, Germany
SNIM RNA stabilized mRNA therapeutics
Entos Pharmaceuticals
Edmonton, Canada
Fusogenix nucleic acid delivery platform
Arrowhead Pharmaceuticals
Pasadena, United States
TRiM RNAi therapeutics platform
Nitto Denko Avecia
Milford, United States
Oligonucleotide and nucleic acid CDMO services
Ajinomoto Bio-Pharma Services
San Diego, United States
CDMO for oligonucleotides and ADCs
Takeda Pharmaceutical
Tokyo, Japan
Global pharma with nanomedicine programs
Astellas Pharma
Tokyo, Japan
Major pharma with nanotechnology drug delivery research
Daiichi Sankyo
Tokyo, Japan
Antibody-drug conjugates and nanomedicine oncology
Eisai Co.
Tokyo, Japan
Neurology and oncology with nanoformulation research
Shionogi & Co.
Osaka, Japan
Infectious disease pharma with nanoparticle research
Otsuka Pharmaceutical
Tokyo, Japan
CNS and oncology pharma with nanomedicine development
Sumitomo Pharma
Osaka, Japan
Regenerative medicine and nanomedicine programs
Chugai Pharmaceutical
Tokyo, Japan
Antibody engineering and innovative drug delivery
LG Chem Life Sciences
Seoul, South Korea
Life sciences division with nanoparticle drug delivery
Samyang Biopharmaceuticals
Seoul, South Korea
Genexol-PM polymeric micelle nanoparticle drugs
Celltrion
Incheon, South Korea
Biosimilars and antibody drug conjugates
Hanmi Pharmaceutical
Seoul, South Korea
LAPSCOVERY long-acting drug delivery platform
Yuhan Corporation
Seoul, South Korea
Korean pharma with nanoformulation programs
Daewoong Pharmaceutical
Seoul, South Korea
Innovative drug delivery and biologics
Hengrui Medicine
Lianyungang, China
Leading Chinese pharma with nanomedicine oncology programs
CSPC Pharmaceutical
Shijiazhuang, China
Major Chinese pharma with nanomedicine research
Hansoh Pharmaceutical
Lianyungang, China
Innovative Chinese pharma with nanoformulation expertise
Zhejiang Medicine
Shaoxing, China
API manufacturer with nano-formulation capabilities
WuXi AppTec
Shanghai, China
Global CRO/CDMO with nanomedicine manufacturing capabilities
Asymchem Laboratories
Tianjin, China
CDMO services including nanoparticle formulations
PharmaBlock Sciences
Nanjing, China
Building blocks and CDMO for nanomedicine synthesis
Livzon Pharmaceutical
Zhuhai, China
Chinese pharma with microsphere and nanoparticle delivery
Luye Pharma Group
Yantai, China
Advanced drug delivery including microspheres and liposomes
Taiwan Liposome Company
Taipei, Taiwan
BioSeizer and NanoX liposomal drug delivery platforms
PharmaEngine
Taipei, Taiwan
Liposomal formulations for cancer treatment
Celsion Corporation
Lawrenceville, United States
ThermoDox heat-activated liposomal doxorubicin
Oncobiologics
Cranbury, United States
Biosimilar development with advanced formulation technology
Sixfold Bioscience
London, United Kingdom
AI-driven nanoparticle delivery optimization
NanoSyrinx
Sheffield, United Kingdom
Bacterial contractile injection system for protein delivery
Nuvation Bio
New York, United States
Precision oncology with targeted drug development
Nano Biotecnologia SA
São Paulo, Brazil
Nanotechnology for cosmetic and pharmaceutical applications
Lonza
Basel, Switzerland
Life sciences and specialty ingredients
Alnylam Pharmaceuticals
Cambridge, United States
Leader in RNAi therapeutics using lipid nanoparticle delivery for genetic diseases
Arbutus Biopharma
Vancouver, Canada
Develops lipid nanoparticle technology for hepatitis B and other infectious diseases
Arcturus Therapeutics
San Diego, United States
RNA medicines company using LUNAR lipid nanoparticle delivery platform
Acuitas Therapeutics
Vancouver, Canada
Develops lipid nanoparticle delivery systems for nucleic acid therapeutics
Genevant Sciences
Cambridge, United States
Lipid nanoparticle and ligand conjugate delivery platforms for genetic medicines
Arrowhead Pharmaceuticals
Pasadena, United States
RNAi therapeutics company developing targeted delivery systems for genetic medicines
Dicerna Pharmaceuticals
Lexington, United States
RNAi therapeutics using GalXC delivery platform for liver-targeted gene silencing
Medtronic
Dublin, Ireland
Medical device company with nanotechnology applications in implants and drug delivery
Abbott Vascular
Santa Clara, United States
Cardiovascular devices with drug-eluting nano-coated stents
Selecta Biosciences
Watertown, United States
ImmTOR biodegradable nanoparticles for immune tolerance induction
Celator Pharmaceuticals
Vancouver, Canada
Liposomal nanoparticle drug delivery for combination cancer therapies
NanOlogy
Fort Worth, United States
Submicron particle technology for localized drug delivery in cancer treatment
Halozyme Therapeutics
San Diego, United States
ENHANZE technology enabling subcutaneous delivery of biologics
Lipocine
Salt Lake City, United States
Lipid-based oral drug delivery platform for poorly bioavailable compounds
Liquidia Technologies
Morrisville, United States
PRINT nanoparticle technology for precisely engineered drug particles
Novavax
Gaithersburg, United States
Recombinant nanoparticle vaccine technology for infectious diseases
Vaxart
South San Francisco, United States
Oral vaccine platform using recombinant vectors and nanoparticle technology
Bharat Biotech
Hyderabad, India
Vaccine developer with nanoparticle-based vaccine platforms
SK Bioscience
Seongnam, South Korea
Vaccine and biopharmaceutical company with nanoparticle vaccine capabilities
Quotient Sciences
Nottingham, United Kingdom
Drug development services including nanoparticle formulation technologies
Particle Sciences
Bethlehem, United States
Drug delivery and formulation development including nanoparticle systems
Catalent
Somerset, United States
Contract manufacturer with lipid nanoparticle and advanced drug delivery capabilities
Lonza Pharma
Basel, Switzerland
Life sciences company with lipid nanoparticle manufacturing for mRNA therapeutics
Evonik Health Care
Essen, Germany
Specialty chemicals for pharmaceutical drug delivery including lipid nanoparticles
Croda Health Care
Snaith, United Kingdom
Specialty ingredients including lipids for nanoparticle drug delivery
Curia Global
Albany, United States
Contract research and manufacturing with nanoparticle drug delivery expertise
Hovione
Loures, Portugal
CDMO with spray-dried nanoparticle and amorphous dispersion technologies
Cambrex
East Rutherford, United States
Contract manufacturer with particle engineering and nanoformulation capabilities
Piramal Pharma Solutions
Mumbai, India
CDMO with capabilities in lipid nanoparticle and advanced drug delivery systems
Siegfried Holding
Zofingen, Switzerland
Pharmaceutical CDMO with particle engineering and formulation capabilities
Recipharm
Stockholm, Sweden
Contract manufacturer with inhaled nanoparticle and specialty drug delivery
Corden Pharma
Basel, Switzerland
CDMO specializing in lipids and lipid nanoparticle manufacturing
Exelead
Indianapolis, United States
CDMO focused on liposomes and lipid nanoparticle drug delivery systems
T&T Scientific
Knoxville, United States
Liposome and lipid nanoparticle preparation equipment and services
Polymun Scientific
Klosterneuburg, Austria
CDMO specializing in liposomal and lipid nanoparticle formulations
Encapsula NanoSciences
Brentwood, United States
Custom liposome and nanoparticle formulation services and products
FormuMax Scientific
Sunnyvale, United States
Liposome products and custom lipid nanoparticle formulation services
Northern Lipids
Vancouver, Canada
CDMO for liposomal and lipid nanoparticle drug delivery formulations
Lipoid GmbH
Ludwigshafen, Germany
Manufacturer of high-purity phospholipids for drug delivery and diagnostics
Avanti Polar Lipids
Alabaster, United States
High-purity lipids and liposomes for research and drug delivery applications
NOF Corporation
Tokyo, Japan
PEG-lipid conjugates and functional lipids for liposome drug delivery
Nanocs
New York, United States
PEGylation reagents and functionalized nanoparticles for biomedical applications
Hong Kong University of Science and Technology
Hong Kong, Hong Kong
Research university with Institute for Advanced Study nanomaterials focus
Evonik Health Care
Essen, Germany
Drug delivery polymers and lipid nanoparticle components
Alnylam Pharmaceuticals
Cambridge, United States
Pioneer in RNAi therapeutics with lipid nanoparticle delivery
Denali Therapeutics
South San Francisco, United States
Neurodegeneration drugs using Transport Vehicle BBB-crossing technology
Voyager Therapeutics
Cambridge, United States
AAV capsid engineering for CNS gene therapy delivery
4D Molecular Therapeutics
Emeryville, United States
Therapeutic vectors using Directed Evolution AAV capsid discovery
Spark Therapeutics
Philadelphia, United States
Gene therapy pioneer (Luxturna) now part of Roche
Generation Bio
Cambridge, United States
Non-viral gene therapy using lipid nanoparticle delivery
Dicerna Pharmaceuticals
Lexington, United States
RNAi therapeutics using GalNAc delivery (acquired by Novo Nordisk)
Curia Global
Albany, United States
CDMO with nanoparticle and complex formulation capabilities
Croda International
Snaith, United Kingdom
Specialty chemicals with Avanti lipids for LNP formulations
Entos Pharmaceuticals
Edmonton, Canada
Fusogenix DNA delivery platform for gene therapy
Laronde
Cambridge, United States
Endless RNA (eRNA) technology for persistent protein expression
Orna Therapeutics
Cambridge, United States
Circular RNA platform for cell therapy and protein replacement
Entrada Therapeutics
Boston, United States
Endosomal Escape Vehicle (EEV) platform for intracellular delivery
Bicycle Therapeutics
Cambridge, United Kingdom
Bicyclic peptide platform for targeted drug delivery
PeptiDream
Kawasaki, Japan
Peptide Drug Discovery Platform System for macrocyclic therapeutics
Sorrento Therapeutics
San Diego, United States
Biopharmaceutical with ADC and nanoparticle delivery platforms
Mersana Therapeutics
Cambridge, United States
Antibody drug conjugates using Dolasynthen platform
ADC Therapeutics
Lausanne, Switzerland
Antibody drug conjugates for hematological malignancies
Seagen
Bothell, United States
ADC pioneer (Adcetris, Padcev) acquired by Pfizer
ImmunoGen
Waltham, United States
ADC technology company acquired by AbbVie
Synaffix
Amsterdam, Netherlands
ADC technology platform using GlycoConnect and toxSYN
Abzena
Cambridge, United Kingdom
ADC development and manufacturing CDMO
Sutro Biopharma
South San Francisco, United States
Cell-free protein synthesis for site-specific ADC conjugation
Bioasis Technologies
Guilford, Canada
xB3 platform for blood-brain barrier crossing drug delivery
AngioChem
Montreal, Canada
Peptide-drug conjugates for CNS delivery across BBB
Applied Genetic Technologies
Alachua, United States
AAV gene therapies for rare ophthalmologic diseases
Lysogene
Paris, France
CNS-targeted gene therapy for lysosomal storage diseases
Ultragenyx Pharmaceutical
Novato, United States
Biopharmaceutical company developing novel products for rare and ultra-rare diseases
Takeda Cell Therapy
Tokyo, Japan
Global pharmaceutical company with advanced cell therapy programs
Daiichi Sankyo ADC
Tokyo, Japan
Global pharmaceutical company with leading ADC technology platform
Exelixis
Alameda, United States
Oncology company developing transformative cancer treatments
Catalent Cell and Gene
Somerset, United States
Global CDMO offering cell therapy, gene therapy, and viral vector manufacturing
uniQure
Amsterdam, Netherlands
Gene therapy company developing AAV-based treatments for severe genetic diseases
Taysha Gene Therapies
Dallas, United States
Gene therapy company developing treatments for monogenic CNS diseases
Insulet Corporation
Acton, United States
Medical device company developing tubeless insulin pump technology
Tandem Diabetes Care
San Diego, United States
Medical device company developing advanced insulin pump technology
Baxter International
Deerfield, United States
Healthcare company focused on products for hospitalized patients
LivaNova
London, United Kingdom
Medical technology company focused on neuromodulation and cardiopulmonary
ICU Medical
San Clemente, United States
Medical device company developing infusion therapy and critical care products
Calibrate
New York, United States
Metabolic health company
pSivida (Eyepoint)
Watertown, United States
Sustained ocular drug delivery
Nanotope
Evanston, United States
Self-assembling peptide nanomaterials
Nanopass Technologies
Ness Ziona, Israel
Microneedle technology for intradermal drug delivery
Nanomi
Oldenzaal, Netherlands
Membrane emulsification for nanoparticle production
ARIZ Precision Medicine
San Diego, United States
Nanotechnology for targeted cancer drug delivery using siRNA nanoparticles
SeraGene Therapeutics
London, United Kingdom
RNA and nanomedicine treatments for blood disorders
Nanoligent
Leuven, Belgium
Oncology nanodrug development
Madrigal Mental Care
Boston, United States
Organic nanoparticle drug delivery for mental health
Theranautilus
Bangalore, India
Nanobots for dental healthcare and root canal disinfection
Nanobiotec
Madrid, Spain
Nanomedicine and drug delivery solutions
Cour Pharmaceutical
Chicago, United States
Particle platforms enabling immune targeting for inflammatory and immune applications
Zylo Therapeutics
Minneapolis, United States
Sustained-release drug-delivery system using hydrogel-derived nanoparticles
iCeutica
Sydney, Australia
Encapsulated Organic Nanoparticles (EON) platform for nano-sized drug particles
Helex
Boston, United States
Lipid nanoparticle technology for targeted drug delivery for kidney diseases
Meda Biotech
Shanghai, China
Hybrid-nanoengineered water soluble drugs optimizing drug trafficking to disease sites
DNA Nanobots
Cambridge, United States
DNA-based nanodevices for targeted therapeutics delivery, vaccines, and diagnostics
Revalesio Corporation
Tacoma, United States
Oxygen delivery technology at nano-scale for therapeutic applications
BioPact
Delft, Netherlands
Nanoformulation technology for drug delivery applications
Mulder Lab
Eindhoven, Netherlands
Nanomedicine research and development services
Nano4Tarmed
Coimbra, Portugal
Nanotechnology platforms for targeted medicine and cancer treatment
Robeauté
Paris, France
Modular swallowable microrobots for targeted medical interventions
Blueberry Therapeutics
Manchester, United Kingdom
Polymer nanoparticles for treating fungal infections with 83% efficacy
Cello Therapeutics
San Diego, United States
Cell membrane-coated nanoparticles for immunotherapy delivery with FDA IND status
Adocia
Lyon, France
BioChaperone nanoformulation technology for improved insulin delivery
Nanocare
Mumbai, India
Silver nanoparticle antimicrobial coatings for textiles and medical applications
Tandem Nano
Boston, United States
Nanoformulation delivery solutions for agriculture and pharmaceuticals
HK Inno.N
Seoul, South Korea
Pharmaceutical nanotechnology for drug delivery systems
Evox Therapeutics
Oxford, United Kingdom
DeliverEX platform for engineered exosome therapeutics
Aruna Bio
Athens, United States
Neural-derived exosomes for CNS drug delivery crossing BBB
ExonanoRNA
Boston, United States
RNA nanoparticles and exosomes for cancer therapeutics
Phosphorex
Hopkinton, United States
CDMO for lipid nanoparticle and liposome drug delivery
DIVERSA Technologies
Santiago de Compostela, Spain
Innovative nanoparticle formulations for drug delivery
DIANT Pharma
San Diego, United States
LiFT continuous manufacturing system for lipid nanoparticles at GMP scale